Epigenetic Reprogramming of the Tumor Microenvironment: An Evidence-Graded Framework from Cell States to Clinical Translation
Year: 2026
Type: article
Abstract: Purpose of Review The tumor microenvironment (TME) is a dynamic multicellular system in which malignant, immune, stromal, vascular, and metabolic compartments adapt to spatial and therapeutic pressure. Epigenetic regulation can stabilize these adaptations without changing DNA sequence, but evidence varies. Transcriptomic heterogeneity alone does not establish epigenetic reprogramming; direct chromatin measurement and causal perturbation are needed to distinguish targetable mechanisms from associated cell states. We assess how directly epigenetic evidence supports claims across TME compartments and where clinical extrapolation remains uncertain. Recent Findings This critical narrative review evaluates an evidence chain linking a regulator to a directly measured chromatin alteration, a defined cellular state, an intercellular consequence, and a context-specific therapeutic outcome. Evidence is graded from transcriptional association through epigenomic measurement and functional perturbation to patient validation and clinical outcomes. The review considers malignant, lymphoid, myeloid, fibroblast, endothelial, spatial, metabolic, and therapeutic contexts, while distinguishing epigenetic mechanisms from environmental inputs and measurement technologies. It asks separately whether treatment engages its proposed target, changes the relevant chromatin state, affects neighboring compartments, and improves patient outcomes. Summary Translation requires compartment-resolved pharmacodynamic assays, biologically informed dosing and sequencing, prospective biomarkers, and trials linking defined epigenetic state changes to meaningful patient benefit. Clinical studies should stratify by disease and cell compartment, report pharmacodynamic evidence, and avoid treating early response as proof of broad utility.
Author: Udayan Bhattacharya
Institutions: University of Michigan, Michigan Medicine
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $2,990
OpenAlex ID: W7236296824
